Calcitonin gene-related peptide (CGRP) receptor antagonists are a class of drugs that act as antagonists of the calcitonin gene-related peptide receptor (CGRPR).
Contents
CGRPR antagonists are under investigation as potential antimigraine agents and also in the context of osteoarthritis.
Examples
TEV-48125 is not a Calcitonin gene-related peptide receptor antagonist but a monoclonal antibody targeting CGRP . Most experimental CGRP inhibitors are monoclonal antibodies given by monthly injections.
Clinical trials
In June 2015 Phase 2 clinical trial data for three different anti-CGRP drugs ( Amgen (AMG 334), Teva Pharmaceuticals (TEV-48125), and Eli Lilly & Co (LY2951742)) were presented at the American Headache Society's (AHS) annual meeting.
In March 2016 Alder reported phase IIb clinical trial data for its ALD403.
By April 2016, Alder, Amgen and Teva had initiated phase III trials.